S. Surapaneni

发表

Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate.

N. Chen, J. Treanor, C. Dominguez, 2007, Journal of medicinal chemistry.

Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamides.

N. Chen, J. Treanor, V. Viswanadhan, 2007, Journal of medicinal chemistry.

Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors.

David P. Carney, P. Gallant, M. Morrison, 2011, Bioorganic & medicinal chemistry letters.

Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib

S. Surapaneni, Fan Wu, G. Krishna, 2020, Cancer Chemotherapy and Pharmacology.

Antihyperalgesic Effects of (R,E)-N-(2-Hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a Novel Transient Receptor Potential Vanilloid Type 1 Modulator That Does Not Cause Hyperthermia in Rats

J. Louis, B. H. Manning, N. Gavva, 2008, Journal of Pharmacology and Experimental Therapeutics.

In vitro inhibition of human nucleoside transporters and uptake of azacitidine by an isocitrate dehydrogenase-2 inhibitor enasidenib and its metabolite AGI-16903

S. Yao, James D Young, S. Surapaneni, 2018, Xenobiotica; the fate of foreign compounds in biological systems.

Pharmacokinetic Characterization of Amrubicin Cardiac Safety in an Ex Vivo Human Myocardial Strip Model. I. Amrubicin Accumulates to a Lower Level than Doxorubicin or Epirubicin

M. Chello, E. Covino, S. Surapaneni, 2012, Journal of Pharmacology and Experimental Therapeutics.

Investigation into MAO B–Mediated Formation of CC112273, a Major Circulating Metabolite of Ozanimod, in Humans and Preclinical Species: Stereospecific Oxidative Deamination of (S)-Enantiomer of Indaneamine (RP101075) by MAO B

V. Shanmugasundaram, D. Dalvie, S. Surapaneni, 2021, Drug Metabolism and Disposition.

Mass Spectrometry‐Based Methodologies for Pharmacokinetic Characterization of Antibody Drug Conjugate Candidates During Drug Development

S. Surapaneni, M. Vallejo, Matthew V. Myers, 2017 .

Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants

S. Surapaneni, S. Zhou, M. Palmisano, 2021, Cancer Chemotherapy and Pharmacology.

Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas

J. Chen, L. Kwak, S. Surapaneni, 2014, Leukemia.

Role of drug metabolism in drug discovery and development

S. Surapaneni, Gondi N. Kumar, 2001, Medicinal research reviews.

Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration

J. Kosek, S. Surapaneni, P. Schafer, 2012, Cancer Chemotherapy and Pharmacology.

Pharmacokinetic Characterization of Amrubicin Cardiac Safety in an Ex Vivo Human Myocardial Strip Model. II. Amrubicin Shows Metabolic Advantages over Doxorubicin and Epirubicin

M. Chello, E. Covino, S. Surapaneni, 2012, Journal of Pharmacology and Experimental Therapeutics.

2017 White Paper on recent issues in bioanalysis: aren't BMV guidance/guidelines 'Scientific'? (Part 1 - LCMS: small molecules, peptides and small molecule biomarkers).

Sam H Haidar, Olivier Le Blaye, Gustavo Mendes Lima Santos, 2017, Bioanalysis.

Role of drug metabolism in drug discovery and development

S. Surapaneni, G N Kumar, S Surapaneni, 2001, Medicinal research reviews.

Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties.

J. Treanor, C. Dominguez, J. Katon, 2007, Journal of medicinal chemistry.

In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine

S. Surapaneni, E. Laille, Gondi N. Kumar, 2010, Cancer Chemotherapy and Pharmacology.

Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects

S. Surapaneni, M. Palmisano, Ying Ye, 2020, European Journal of Clinical Pharmacology.

In vitro metabolism of a novel JNK inhibitor tanzisertib: interspecies differences in oxido-reduction and characterization of enzymes involved in metabolism

S. Surapaneni, M. Moghaddam, M. Hoffmann, 2015, Xenobiotica; the fate of foreign compounds in biological systems.

A preliminary pharmacokinetic study of the enantiomers of the terfenadine acid metabolite in humans.

S. Surapaneni, S. K. Khalil, 1994, Chirality.

Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults

S. Surapaneni, S. Zhou, M. Palmisano, 2022, Cancer Chemotherapy and Pharmacology.

Absorption, distribution, metabolism, and excretion of mTOR kinase inhibitor CC-223 in rats, dogs, and humans

S. Surapaneni, Yan Li, Xiaomin Wang, 2019, Xenobiotica; the fate of foreign compounds in biological systems.

Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator

Peijin Zhang, R. Hargreaves, D. Dalvie, 2021, Drug Metabolism and Disposition.

Excretion balance and pharmacokinetics following a single oral dose of [14C]-fedratinib in healthy subjects

S. Surapaneni, M. Palmisano, K. Ogasawara, 2020, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects

S. Surapaneni, N. Chen, H. Lau, 2011, Cancer Chemotherapy and Pharmacology.

Biosynthesis of Drug Metabolites Using Microbes in Hollow Fiber Cartridge Reactors: Case Study of Diclofenac Metabolism by Actinoplanes Species

R. Subramanian, S. Surapaneni, G. Skiles, 2008, Drug Metabolism and Disposition.

ABT-963 [2-(3,4-Difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], A Highly Potent and Selective Disubstituted Pyridazinone Cyclooxgenase-2 Inhibitor

G. Carter, S. Surapaneni, K. Marsh, 2004, Journal of Pharmacology and Experimental Therapeutics.

The Vanilloid Receptor TRPV1 Is Tonically Activated In Vivo and Involved in Body Temperature Regulation

J. Treanor, T. Juan, J. Louis, 2007, The Journal of Neuroscience.

Resolution of terfenadine enantiomers by reversed phase-high performance liquid chromatography using beta-cyclodextrin as mobile phase additive.

S. Surapaneni, S. K. Khalil, 1996, Journal of pharmaceutical and biomedical analysis.

A sensitive HPLC method for the determination of terfenadine and its metabolite in human plasma

S. Surapaneni, S. K. Khalil, 1994 .

Contribution of Metabolites to P450 Inhibition–Based Drug–Drug Interactions: Scholarship from the Drug Metabolism Leadership Group of the Innovation and Quality Consortium Metabolite Group

W. Humphreys, R. Walsky, C. Prakash, 2015, Drug Metabolism and Disposition.

Characterization and optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption.

Ping Gao, Sekhar Surapaneni, P. Gao, 2009, Journal of pharmaceutical sciences.

The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics.

Sekhar Surapaneni, Sesha Neervannan, R. Syed, 2008, Journal of pharmaceutical sciences.

Stereoselective metabolism of tazofelone, an anti-inflammatory bowel disease agent, in rats and dogs and in human liver microsomes.

M. Clay, T. Lindstrom, S. Surapaneni, 1999, Chirality.

Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans

Mark J. Rose, Andrej A. Romanovsky, A. A. Romanovsky, 2008, PAIN.

Radiolabeled mass-balance excretion and metabolism studies in laboratory animals: a commentary on why they are still necessary

C. Prakash, F. Tse, S. Surapaneni, 2013, Xenobiotica; the fate of foreign compounds in biological systems.

Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study.

Ping Gao, Sekhar Surapaneni, P. Gao, 2008, Molecular pharmaceutics.

Disposition, metabolism and mass balance of [14C]apremilast following oral administration

S. Surapaneni, P. Schafer, O. Laskin, 2011, Xenobiotica; the fate of foreign compounds in biological systems.

In vitro biotransformation and identification of human cytochrome P450 isozyme-dependent metabolism of tazofelone.

M. Clay, T. Lindstrom, S. Surapaneni, 1997, Drug metabolism and disposition: the biological fate of chemicals.

Contribution of Metabolites to P 450 Inhibition – Based Drug – Drug Interactions : Scholarship from the Drug Metabolism Leadership Group of the Innovation and Quality Consortium Metabolite Group s

W. Humphreys, R. Walsky, C. Prakash, 2015 .

Assessment of drug-drug interactions of CC-90001, a potent and selective inhibitor of c-Jun N-terminal kinase

D. Tatosian, S. Surapaneni, F. Ramírez-Valle, 2021, Xenobiotica; the fate of foreign compounds in biological systems.

Preclinical Development of Oncology Drugs

S. Surapaneni, H. Oh, J. Hui, 2017 .

Chapter 23 – Preclinical Development of Oncology Drugs

S. Surapaneni, H. Oh, J. Hui, 2013 .

Use of 4β-hydroxycholesterol in animal and human plasma samples as a biomarker for CYP3A induction.

Y. Liu, S. Surapaneni, M. Vallejo, 2016, Bioanalysis.

Absorption, distribution, metabolism and excretion of an isocitrate dehydrogenase-2 inhibitor enasidenib in rats and humans

Hua Yang, S. Surapaneni, Yan Li, 2019, Xenobiotica; the fate of foreign compounds in biological systems.

Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists.

P. Chakrabarti, E. Doherty, A. Bannon, 2008, Journal of medicinal chemistry.

IDENTIFICATION OF A NOVEL IN VITRO METABONATE FROM LIVER MICROSOMAL INCUBATIONS

Q. Zeng, Chun Li, S. Surapaneni, 2006, Drug Metabolism and Disposition.

Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.

S. Surapaneni, M. Hoffmann, Rangaraj Narayanan, 2016, Drug metabolism letters.

In Vitro Metabolism of the Novel, Highly Selective Oral Angiogenesis Inhibitor Motesanib Diphosphate in Preclinical Species and in Humans

L. Poppe, Chun Li, R. Subramanian, 2009, Drug Metabolism and Disposition.

Repeated Administration of Vanilloid Receptor TRPV1 Antagonists Attenuates Hyperthermia Elicited by TRPV1 Blockade

J. Treanor, L. Arik, C. Henley, 2007, Journal of Pharmacology and Experimental Therapeutics.

ADME-enabling technologies in drug design and development

Sekhar Surapaneni, Donglu Zhang, S. Surapaneni, 2012 .

Appendix: Drug Metabolizing Enzymes and Biotransformation Reactions

S. Surapaneni, Donglu Zhang, 2012 .

Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells

V. Mamidipudi, R. Chopra, S. Surapaneni, 2012, Cancer Chemotherapy and Pharmacology.

Cytochrome P450-mediated epoxidation of 2-aminothiazole-based AKT inhibitors: identification of novel GSH adducts and reduction of metabolic activation through structural changes guided by in silico and in vitro screening.

Q. Zeng, G. E. Wohlhieter, Guomin Yao, 2010, Chemical research in toxicology.

Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach

S. Surapaneni, S. Zhou, M. Palmisano, 2021, Cancer Chemotherapy and Pharmacology.

The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug–drug interactions

S. Surapaneni, Z. Tong, Usha Yerramilli, 2014, Cancer Chemotherapy and Pharmacology.

Bioanalytical Methods for Characterization of CAR‐T Cellular Kinetics: Comparison of PCR Assays and Matrices

M. Masilamani, S. Surapaneni, V. Jawa, 2023, Clinical pharmacology and therapeutics.

ABT-963, A Highly Potent and Selective Disubstituted Pyridazinone COX-2 Inhibitor

G. Carter, S. Surapaneni, M. Jarvis, 2004 .

Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study.

P. Gao, A. Akrami, S. Surapaneni, 2008, Molecular pharmaceutics.

J. Louis, B. H. Manning, N. Gavva, 2008, Journal of Pharmacology and Experimental Therapeutics.